Trends in the use of routine therapies in cystic fibrosis: 1995-2005

Michael W. Konstan, Donald R. Vandevanter, Lawrence Rasouliyan, David J. Pasta, Ashley Yegin, Wayne J Morgan, Jeffrey S. Wagener

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Many therapies are used to treat manifestations of cystic fibrosis (CF). Trends in routine therapy use in Epidemiologic Study of Cystic Fibrosis patients were studied from 1995 to 2005. Patients (15,087) were assessed in 1995; 12,778 in 2005. Observed differences in therapy use of ≤yen;2% were statistically significant at P<0.001. Comparing the 1995 and 2005 populations, mean age was 13.9 versus 15.5 years; weight-for-age percentile was 30.3 versus 36.9; and mean forced expiratory volume in 1sec (FEV1) was 73.7% (na=7065) versus 78.7% (na=7867) predicted. Use of several therapies increased, including airway clearance (69.9-89.6%), inhaled bronchodilators (72.0-84.0%), dornase alfa (44.8-67.2%), inhaled corticosteroids (16.0-49.3%), inhaled antibiotics (6.5-43.1%), oral nutritional supplements (18.3-24.5%), and insulin/oral hypoglycemic agents (4.9-10.2%). Use of mast cell stabilizers (from 22.0% to 5.3%) and oral bronchodilators (from 10.4% to 1.5%) decreased. Less dramatic changes occurred for pancreatic enzymes (92.6-91.0%), oral nonquinolone antibiotics (44.7-39.8%), oral corticosteroids (7.8-5.2%), mucolytics (4.4-2.5%), NSAIDs/high-dose ibuprofen (3.6-3.3%), enteral nutrition (5.2% vs. 8.2%), and oxygen (4.7-4.5%). Therapies not tracked in 1995 were evident in 2005, including oral macrolide antibiotics (33.8%), leukotriene inhibitors/antagonists (10.8%), and inhaled hypertonic saline (2.6%). Routine therapies were generally used more often by older patients and those with lower FEV1. Notable increases in use of therapies, particularly of inhaled therapies, suggest that overall patient treatment burden must have risen correspondingly.

Original languageEnglish (US)
Pages (from-to)1167-1172
Number of pages6
JournalPediatric Pulmonology
Volume45
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Cystic Fibrosis
Therapeutics
Bronchodilator Agents
Forced Expiratory Volume
Anti-Bacterial Agents
Adrenal Cortex Hormones
Expectorants
Leukotriene Antagonists
Ibuprofen
Macrolides
Enteral Nutrition
Non-Steroidal Anti-Inflammatory Agents
Hypoglycemic Agents
Mast Cells
Epidemiologic Studies
Insulin
Oxygen
Weights and Measures
Enzymes
Population

Keywords

  • cystic fibrosis
  • epidemiology
  • therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Konstan, M. W., Vandevanter, D. R., Rasouliyan, L., Pasta, D. J., Yegin, A., Morgan, W. J., & Wagener, J. S. (2010). Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatric Pulmonology, 45(12), 1167-1172. https://doi.org/10.1002/ppul.21315

Trends in the use of routine therapies in cystic fibrosis : 1995-2005. / Konstan, Michael W.; Vandevanter, Donald R.; Rasouliyan, Lawrence; Pasta, David J.; Yegin, Ashley; Morgan, Wayne J; Wagener, Jeffrey S.

In: Pediatric Pulmonology, Vol. 45, No. 12, 12.2010, p. 1167-1172.

Research output: Contribution to journalArticle

Konstan, MW, Vandevanter, DR, Rasouliyan, L, Pasta, DJ, Yegin, A, Morgan, WJ & Wagener, JS 2010, 'Trends in the use of routine therapies in cystic fibrosis: 1995-2005', Pediatric Pulmonology, vol. 45, no. 12, pp. 1167-1172. https://doi.org/10.1002/ppul.21315
Konstan MW, Vandevanter DR, Rasouliyan L, Pasta DJ, Yegin A, Morgan WJ et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatric Pulmonology. 2010 Dec;45(12):1167-1172. https://doi.org/10.1002/ppul.21315
Konstan, Michael W. ; Vandevanter, Donald R. ; Rasouliyan, Lawrence ; Pasta, David J. ; Yegin, Ashley ; Morgan, Wayne J ; Wagener, Jeffrey S. / Trends in the use of routine therapies in cystic fibrosis : 1995-2005. In: Pediatric Pulmonology. 2010 ; Vol. 45, No. 12. pp. 1167-1172.
@article{fe8a3a2deace45308e7563efb2e4ff52,
title = "Trends in the use of routine therapies in cystic fibrosis: 1995-2005",
abstract = "Many therapies are used to treat manifestations of cystic fibrosis (CF). Trends in routine therapy use in Epidemiologic Study of Cystic Fibrosis patients were studied from 1995 to 2005. Patients (15,087) were assessed in 1995; 12,778 in 2005. Observed differences in therapy use of ≤yen;2{\%} were statistically significant at P<0.001. Comparing the 1995 and 2005 populations, mean age was 13.9 versus 15.5 years; weight-for-age percentile was 30.3 versus 36.9; and mean forced expiratory volume in 1sec (FEV1) was 73.7{\%} (na=7065) versus 78.7{\%} (na=7867) predicted. Use of several therapies increased, including airway clearance (69.9-89.6{\%}), inhaled bronchodilators (72.0-84.0{\%}), dornase alfa (44.8-67.2{\%}), inhaled corticosteroids (16.0-49.3{\%}), inhaled antibiotics (6.5-43.1{\%}), oral nutritional supplements (18.3-24.5{\%}), and insulin/oral hypoglycemic agents (4.9-10.2{\%}). Use of mast cell stabilizers (from 22.0{\%} to 5.3{\%}) and oral bronchodilators (from 10.4{\%} to 1.5{\%}) decreased. Less dramatic changes occurred for pancreatic enzymes (92.6-91.0{\%}), oral nonquinolone antibiotics (44.7-39.8{\%}), oral corticosteroids (7.8-5.2{\%}), mucolytics (4.4-2.5{\%}), NSAIDs/high-dose ibuprofen (3.6-3.3{\%}), enteral nutrition (5.2{\%} vs. 8.2{\%}), and oxygen (4.7-4.5{\%}). Therapies not tracked in 1995 were evident in 2005, including oral macrolide antibiotics (33.8{\%}), leukotriene inhibitors/antagonists (10.8{\%}), and inhaled hypertonic saline (2.6{\%}). Routine therapies were generally used more often by older patients and those with lower FEV1. Notable increases in use of therapies, particularly of inhaled therapies, suggest that overall patient treatment burden must have risen correspondingly.",
keywords = "cystic fibrosis, epidemiology, therapy",
author = "Konstan, {Michael W.} and Vandevanter, {Donald R.} and Lawrence Rasouliyan and Pasta, {David J.} and Ashley Yegin and Morgan, {Wayne J} and Wagener, {Jeffrey S.}",
year = "2010",
month = "12",
doi = "10.1002/ppul.21315",
language = "English (US)",
volume = "45",
pages = "1167--1172",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Trends in the use of routine therapies in cystic fibrosis

T2 - 1995-2005

AU - Konstan, Michael W.

AU - Vandevanter, Donald R.

AU - Rasouliyan, Lawrence

AU - Pasta, David J.

AU - Yegin, Ashley

AU - Morgan, Wayne J

AU - Wagener, Jeffrey S.

PY - 2010/12

Y1 - 2010/12

N2 - Many therapies are used to treat manifestations of cystic fibrosis (CF). Trends in routine therapy use in Epidemiologic Study of Cystic Fibrosis patients were studied from 1995 to 2005. Patients (15,087) were assessed in 1995; 12,778 in 2005. Observed differences in therapy use of ≤yen;2% were statistically significant at P<0.001. Comparing the 1995 and 2005 populations, mean age was 13.9 versus 15.5 years; weight-for-age percentile was 30.3 versus 36.9; and mean forced expiratory volume in 1sec (FEV1) was 73.7% (na=7065) versus 78.7% (na=7867) predicted. Use of several therapies increased, including airway clearance (69.9-89.6%), inhaled bronchodilators (72.0-84.0%), dornase alfa (44.8-67.2%), inhaled corticosteroids (16.0-49.3%), inhaled antibiotics (6.5-43.1%), oral nutritional supplements (18.3-24.5%), and insulin/oral hypoglycemic agents (4.9-10.2%). Use of mast cell stabilizers (from 22.0% to 5.3%) and oral bronchodilators (from 10.4% to 1.5%) decreased. Less dramatic changes occurred for pancreatic enzymes (92.6-91.0%), oral nonquinolone antibiotics (44.7-39.8%), oral corticosteroids (7.8-5.2%), mucolytics (4.4-2.5%), NSAIDs/high-dose ibuprofen (3.6-3.3%), enteral nutrition (5.2% vs. 8.2%), and oxygen (4.7-4.5%). Therapies not tracked in 1995 were evident in 2005, including oral macrolide antibiotics (33.8%), leukotriene inhibitors/antagonists (10.8%), and inhaled hypertonic saline (2.6%). Routine therapies were generally used more often by older patients and those with lower FEV1. Notable increases in use of therapies, particularly of inhaled therapies, suggest that overall patient treatment burden must have risen correspondingly.

AB - Many therapies are used to treat manifestations of cystic fibrosis (CF). Trends in routine therapy use in Epidemiologic Study of Cystic Fibrosis patients were studied from 1995 to 2005. Patients (15,087) were assessed in 1995; 12,778 in 2005. Observed differences in therapy use of ≤yen;2% were statistically significant at P<0.001. Comparing the 1995 and 2005 populations, mean age was 13.9 versus 15.5 years; weight-for-age percentile was 30.3 versus 36.9; and mean forced expiratory volume in 1sec (FEV1) was 73.7% (na=7065) versus 78.7% (na=7867) predicted. Use of several therapies increased, including airway clearance (69.9-89.6%), inhaled bronchodilators (72.0-84.0%), dornase alfa (44.8-67.2%), inhaled corticosteroids (16.0-49.3%), inhaled antibiotics (6.5-43.1%), oral nutritional supplements (18.3-24.5%), and insulin/oral hypoglycemic agents (4.9-10.2%). Use of mast cell stabilizers (from 22.0% to 5.3%) and oral bronchodilators (from 10.4% to 1.5%) decreased. Less dramatic changes occurred for pancreatic enzymes (92.6-91.0%), oral nonquinolone antibiotics (44.7-39.8%), oral corticosteroids (7.8-5.2%), mucolytics (4.4-2.5%), NSAIDs/high-dose ibuprofen (3.6-3.3%), enteral nutrition (5.2% vs. 8.2%), and oxygen (4.7-4.5%). Therapies not tracked in 1995 were evident in 2005, including oral macrolide antibiotics (33.8%), leukotriene inhibitors/antagonists (10.8%), and inhaled hypertonic saline (2.6%). Routine therapies were generally used more often by older patients and those with lower FEV1. Notable increases in use of therapies, particularly of inhaled therapies, suggest that overall patient treatment burden must have risen correspondingly.

KW - cystic fibrosis

KW - epidemiology

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=78649647554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649647554&partnerID=8YFLogxK

U2 - 10.1002/ppul.21315

DO - 10.1002/ppul.21315

M3 - Article

C2 - 20717935

AN - SCOPUS:78649647554

VL - 45

SP - 1167

EP - 1172

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 12

ER -